DEVELOPMENT OF ANTICERAMIDE TREATMENT AS A NOVEL MEDICAL COUNTERMEASURE FOR ACUTE EFFECTS OF RADIATION EXPOSURE

Ceramethon正在开发CX-01，这是一种有前途的放射医学对策（MCM），可解决导致后续GI器官衰竭和死亡的辐射诱导微血管（内皮）损伤。CX-01抑制放射损伤和微血管内皮细胞凋亡的起始事件。目前，还没有FDA批准的胃肠道急性辐射综合征（GI-ARS）的治疗方法。对不断增加的辐射暴露的生物学反应的复杂性导致了动物研究平台的持续发展，用于可靠地模拟不同阶段的电离辐射（IR）诱导的损伤，并在战术上应用于测试新型MCM。

Ceramedix is developing CX-01, a promising radiation medical countermeasure (MCM), that addresses radiation-induced microvascular (endothelial) injury that leads to subsequent GI organ failure and death. CX-01 inhibits the initiating event of radiation injury and microvascular endothelial apoptosis. Currently, there are no FDA-approved treatments for gastrointestinal acute radiation syndrome (GI-ARS) The complexity of the biological responses to escalating radiation exposures has led to continued development of animal research platforms for reliably modeling different stages of ionizing radiation (IR) induced injury with tactical application to testing novel MCMs.